| Dr William A Robison, PSYD, LP, LMFT | |
|
1350 E Bradford Pkwy, Springfield, MO 65804-4376 | |
| (417) 761-5850 | |
| Not Available |
| Full Name | Dr William A Robison |
|---|---|
| Gender | Male |
| Speciality | Psychologist - Clinical |
| Location | 1350 E Bradford Pkwy, Springfield, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487868899 | NPI | - | NPPES |
| 2007028986 | Other | MO | STATE COMMITTEE OF PSYCHOLOGY LICENSE NUMBER |
| 494071301 | Medicaid | MO | |
| 2007030433 | Other | MO | STATE COMMITTEE FOR MARRIAGE AND FAMILY THERAPIST LICENSE NUMBER |
| 50373 | Other | NATIONAL REGISTER OF HEALTH SERVICE PROVIDERS IN PSYCHOLOGY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | 2007030433 (Missouri) | Secondary |
| 103TC0700X | Psychologist - Clinical | 2007028986 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr William A Robison, PSYD, LP, LMFT 1300 E Bradford Pkwy, Springfield, MO 65804-4264 Ph: (417) 761-5000 | Dr William A Robison, PSYD, LP, LMFT 1350 E Bradford Pkwy, Springfield, MO 65804-4376 Ph: (417) 761-5850 |
News Archive
NeuroSigma, Inc., a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Veterans Affairs for a clinical trial to evaluate the benefits of non-invasive, external Trigeminal Nerve Stimulation (eTNS) for patients with traumatic brain injury (TBI) in a Phase I clinical trial.
Roche Molecular Systems, Inc. announced today a research collaboration with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) providing Merck access to Roche's developmental microarray-based AmpliChip p53 Test, which is designed to detect mutations in the tumor suppressor gene p53. By identifying cancers that harbor a dysfunctional p53 gene, the companies aim to achieve better treatment outcomes in cancer patients by determining which patients are most likely to respond to certain investigational therapeutic candidates.
A new study released today in the Journal of Virology gives insights into how the HIV-1 virus, which often persists in the body despite antiretroviral treatment, reemerges when treatment stops. More importantly, the study also gives clues on how to stop this reemergence from occurring.
A new method to monitor epidemics like COVID-19 gives an accurate real-time estimate of the growth rate of an epidemic by carefully evaluating the relationship between the amount of viruses in infected people's bodies, called the viral load, and how fast the number of cases is increasing or decreasing.
› Verified 4 days ago